1-4 of 4
Michael Crump
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma

Michinori Ogura, Kensei Tobinai, Kiyohiko Hatake, Andrew Davies, Michael Crump, Revathi Ananthakrishnan, Taro Ishibashi, M. Luisa Paccagnella, Joseph Boni, Erik Vandendries, David MacDonald
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (19): 4807–4816.
https://doi.org/10.1158/1078-0432.CCR-15-2488
Published: 02 October 2016
View articletitled, Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma
Open the PDF for Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas

Ryan D. Morin, Sarit Assouline, Miguel Alcaide, Arezoo Mohajeri, Rebecca L. Johnston, Lauren Chong, Jasleen Grewal, Stephen Yu, Daniel Fornika, Kevin Bushell, Torsten Holm Nielsen, Tina Petrogiannis-Haliotis, Michael Crump, Axel Tosikyan, Bruno M. Grande, David MacDonald, Caroline Rousseau, Maryam Bayat, Pierre Sesques, Remi Froment, Marco Albuquerque, Yury Monczak, Kathleen Klein Oros, Celia Greenwood, Yasser Riazalhosseini, Madeleine Arseneault, Errol Camlioglu, André Constantin, Qiang Pan-Hammarstrom, Roujun Peng, Koren K. Mann, Nathalie A. Johnson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (9): 2290–2300.
https://doi.org/10.1158/1078-0432.CCR-15-2123
Published: 01 May 2016
View articletitled, Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas
Open the PDF for Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas in another window
Includes: Supplementary data
Journal Articles

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Bertrand Coiffier, Weimin Li, Erin D. Henitz, Jayaprakash D. Karkera, Reyna Favis, Dana Gaffney, Alice Shapiro, Panteli Theocharous, Yusri A. Elsayed, Helgi van de Velde, Michael E. Schaffer, Evgenii A. Osmanov, Xiaonan Hong, Adriana Scheliga, Jiri Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Joanna Romejko-Jarosinska, Sven de Vos, Michael Crump, Ofer Shpilberg, Pier Luigi Zinzani, Andrew Cakana, Dixie-Lee Esseltine, George Mulligan, Deborah Ricci
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (9): 2551–2561.
https://doi.org/10.1158/1078-0432.CCR-12-3069
Published: 30 April 2013
View articletitled, Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
Open the PDF for Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab in another window
Includes: Supplementary data
Journal Articles

High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma

Rena Buckstein, Robert S. Kerbel, Yuval Shaked, Rakesh Nayar, Cindy Foden, Ruth Turner, Christine R. Lee, Diane Taylor, Liying Zhang, Shan Man, Sylvain Baruchel, Diana Stempak, Francesco Bertolini, Michael Crump
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5190–5198.
https://doi.org/10.1158/1078-0432.CCR-06-0474
Published: 01 September 2006
View articletitled, High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma
Open the PDF for High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma in another window